Compare HAS & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HAS | SNN |
|---|---|---|
| Founded | 1923 | 1856 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Industrial Specialties |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.3B | 12.3B |
| IPO Year | 1994 | 2002 |
| Metric | HAS | SNN |
|---|---|---|
| Price | $117.56 | $30.18 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 14 | 6 |
| Target Price | ★ $119.08 | $32.32 |
| AVG Volume (30 Days) | ★ 2.4M | 1.2M |
| Earning Date | 10-20-2026 | 08-04-2026 |
| Dividend Yield | 2.37% | ★ 2.53% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 5.27 | N/A |
| Revenue | ★ $5,365,900,000.00 | N/A |
| Revenue This Year | $9.87 | $4.75 |
| Revenue Next Year | $7.20 | $5.15 |
| P/E Ratio | ★ $22.49 | $64.97 |
| Revenue Growth | ★ 13.06 | N/A |
| 52 Week Low | $74.78 | $26.30 |
| 52 Week High | $121.04 | $37.09 |
| Indicator | HAS | SNN |
|---|---|---|
| Relative Strength Index (RSI) | 79.47 | 61.82 |
| Support Level | $86.83 | $29.18 |
| Resistance Level | N/A | $30.52 |
| Average True Range (ATR) | 3.25 | 0.47 |
| MACD | 0.79 | 0.08 |
| Stochastic Oscillator | 87.24 | 62.64 |
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Peppa Pig, and Magic: The Gathering. The firm acquired EOne in 2019, bolting on popular family properties like Peppa Pig and PJ Masks, and has since divested noncore lines from the tie-up. Furthermore, the addition of Dungeons & Dragons Beyond in 2022 offers the firm access to around 20 million digital tabletop players.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 40% of the UK-based firm's revenue comes from orthopedic products, and another 31% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the US, just over 30% is from other developed markets, and emerging markets account for the remainder.